Female sex hormone helps protect against hearing loss

Our hearing is one of the wonders of the human body which is all too often taken for granted. Like many things in life, we don't really appreciate our ability to hear clearly until we begin to lose it. As we age, our ability to discern sounds begins to deteriorate. Therefore, new innovative therapies to guard the hearing of patients are eagerly sought after. Sometimes these treatments can come from unexpected sources, such as the 'female sex hormone' estradiol.

A team of researchers from Sweden's prestigious Karolinska Institute studied the role of estradiol in hearing loss recovery by examining mice with deficiencies in various estrogen receptors. They found that mice of both sexes deficient in only one estrogen receptor had reduced recovery from auditory trauma and that treatment with estrogen receptor drugs protected the animals against auditory damage. Their findings have recently been published in the Journal of Clinical Investigation (JCI).

Estradiol is a sex hormone, which although labeled 'female', is found in both men and women. In women, estradiol acts as a growth hormone for tissue of the reproductive organs and plays a critical role in sexual development. In men, the hormone is generated in testosterone by aromatase, a protein which is found throughout the male reproductive system and shares in the development of sperm.

In addition to the critical role it plays in reproductive and sexual functioning, Estradiol is also known to affect other organs. Not only does it regulate bone formation and cardiovascular tone in elderly men, the hormone is known to help maintain cell survival within the central nervous system of both sexes.

Previous clinical and experimental studies have also indicated that estradiol plays a significant role in auditory physiology. In women, it was found that hearing thresholds vary with sex hormone levels during the menstrual cycle, and postmenopausal women have higher auditory brainstem response (ABR) thresholds than younger women or men. These studies indicate a protective function of estradiol in the female auditory system.

However, until now, little was known about the impact of estradiol-binding proteins known as estrogen receptors (ERs) on hearing or whether there are sex specific facets in the inner ear. In this latest investigation, the scientists from the Karolinska Institute examined the role of known estrogen receptors in response to auditory damage. This was done by testing hearing loss recovery in mice that had deficiencies in various estrogen receptors.

Researchers found that mice only lacking in the estrogen receptor ER-beta recovered less well from hearing loss. They also discovered that treatment with ER-beta-binding drugs protected mice from auditory damage. In addition, not only was ER-beta found in the ears of mice of both sexes, but levels of brain-derived neurotrophic factor (BDNF), a protein which protects nerves, were found to be lower in mice that lacked either ER-beta or aromatase.

These findings are the first experimental evidence directly linking ER expression to the protection of auditory function.The researchers involved in the study are confident that their findings will now pave the way for the development of new treatments against hearing loss.

For further information, please visit:
http://jci.org

Copyright ©European Communities, 2008
Neither the Office for Official Publications of the European Communities, nor any person acting on its behalf, is responsible for the use, which might be made of the attached information. The attached information is drawn from the Community R&D Information Service (CORDIS). The CORDIS services are carried on the CORDIS Host in Luxembourg - http://cordis.europa.eu. Access to CORDIS is currently available free-of-charge.

Most Popular Now

Pfizer and BioNTech complete submission to Europea…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced they have completed a submission to the European Medicines Agency (EMA) for an Omicron-adapted biva...

Lilly will supply an additional 150,000 doses of b…

Eli Lilly and Company (NYSE: LLY) announced a modified purchase agreement with the U.S. government to supply an additional 150,000 doses of bebtelovimab for approximately...

Bayer to sell men's health product Nebido™ to Grün…

Bayer and Grünenthal have entered into a definitive agreement regarding the sale of Bayer's men's health product Nebido™ (testosterone undecanoate), for a purchase price ...

AstraZeneca to acquire TeneoTwo and its clinical-s…

AstraZeneca announced an agreement to acquire TeneoTwo, Inc. (TeneoTwo)i, including its Phase I clinical-stage CD19/CD3 T-cell engager, TNB-486, currently under evaluatio...

Demonstration of a potent, universal coronavirus m…

The SARS-CoV-2 that causes COVID-19 has killed 6.3 million people worldwide since 2019, painfully highlighting the vulnerability of humanity to novel coronaviruses. Re...

The fourth COVID-19 vaccine reduces the risk of de…

A new study by Tel Aviv University and Ben Gurion University of the Negev, in collaboration with the Israeli Ministry of Health, has found that the fourth COVID-19 vaccin...

Vaccine protection against COVID-19 short-lived, b…

Since COVID-19 vaccines first became available to protect against infection and severe illness, there has been much uncertainty about how long the protection lasts, and w...

Research shows investigational drug fosters nerve …

Scientists from the University of Birmingham have shown that a brain-penetrating candidate drug currently in development as a cancer therapy can foster regeneration of da...

NIH launches clinical trial of mRNA Nipah virus va…

The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, has launched an early-stage clinical trial evaluating an inv...

Anti-inflammatory compound shows potential in trea…

An anti-inflammatory compound may have the potential to treat systemic inflammation and brain injury in patients with severe COVID-19 and significantly reduce their chanc...

Vaccine-induced immune response to omicron wanes s…

Although COVID-19 booster vaccinations in adults elicit high levels of neutralizing antibodies against the Omicron variant of SARS-CoV-2, antibody levels decrease substan...

SARS-CoV-2 hijacks nanotubes between neurons to in…

COVID-19 often leads to neurological symptoms, such as a loss of taste or smell, or cognitive impairments (including memory loss and concentration difficulties), both dur...